8-K: Cocrystal Pharma Grants Stock Options, Cash Award

Cocrystal Pharma's Compensation Committee approved non-qualified stock options for directors, executive officers, and a consultant, alongside a cash award for Dr. Roger Kornberg.

Summary

• The Compensation Committee of Cocrystal Pharma, Inc. approved the grant of non-qualified stock options to directors, executive officers, and a consultant on January 9, 2026.
• These options are granted under the company's 2025 Equity Incentive Plan, have a 10-year term, and are exercisable at the closing price of January 8, 2026.
• Vesting for the options is structured with one-half becoming exercisable on January 9, 2027, and the remaining half vesting in eight equal quarterly installments starting March 31, 2027, contingent on continued service.
• Key recipients and their total stock option grants include Dr. Roger Kornberg (24,615), Dr. Philip Frost (24,615), Steve Rubin (16,410), Fred Hassan (16,410), Richard Pfenniger (16,410), Anthony Japour (16,410), James Martin (49,229), Sam Lee (49,229), and a consultant (40,000).
• A $50,000 cash award was also approved for Dr. Roger Kornberg for his service as chairman of the company's Scientific Advisory Board.

Sentiment

Score: 6

Explanation: The filing details routine equity and cash compensation for key personnel, which is a standard practice to incentivize and retain talent. While it represents an expense, it also aligns management and director interests with shareholder value, indicating a neutral to slightly positive sentiment.

Positives

• The grant of stock options aligns the interests of directors, executive officers, and a consultant with those of shareholders, incentivizing long-term performance.
• The cash award recognizes Dr. Roger Kornberg's contribution as chairman of the Scientific Advisory Board.

Negatives

• The issuance of stock options could lead to potential dilution for existing shareholders if a significant number are exercised.
• The compensation represents an expense for the company, impacting its financial statements.

Future Outlook

NA

Industry Context

This compensation update is an internal corporate governance matter and does not directly relate to broader industry trends or competitive landscape within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: Potential for future dilution upon option exercise, but also benefit from aligned interests of management and directors.
• Executive Officers, Directors, and Consultant: Receive incentives for continued service and performance.

Next Steps

• Execution of the company's form of Non-Qualified Stock Option Agreement by recipients.
• Vesting of one-half of the options on January 9, 2027.
• Commencement of quarterly vesting for the remaining half of the options on March 31, 2027.

Key Dates

Keywords

Cocrystal Pharma, COCP, stock options, equity incentive plan, executive compensation, director compensation, non-qualified stock options, pharmaceutical